Literature DB >> 23114843

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Shazia Irshad1, Cory Abate-Shen.   

Abstract

More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced. These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23114843      PMCID: PMC3584242          DOI: 10.1007/s10555-012-9409-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  119 in total

1.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Authors:  Mei-Ling Chen; Pei-Zhang Xu; Xiao-ding Peng; William S Chen; Grace Guzman; Ximing Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Nissim Hay
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

2.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

Authors:  Helen B Pearson; Pedro A Perez-Mancera; Lukas E Dow; Andrew Ryan; Pierre Tennstedt; Debora Bogani; Imogen Elsum; Andy Greenfield; David A Tuveson; Ronald Simon; Patrick O Humbert
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

3.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

4.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Authors:  Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

5.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

7.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

8.  Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten.

Authors:  Stéphanie A Backman; Danny Ghazarian; Kelvin So; Otto Sanchez; Kay-Uwe Wagner; Lothar Hennighausen; Akira Suzuki; Ming-Sound Tsao; William B Chapman; Vuk Stambolic; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-27       Impact factor: 11.205

9.  Sox9 is required for prostate development.

Authors:  Martin K Thomsen; Christopher M Butler; Michael M Shen; Amanda Swain
Journal:  Dev Biol       Date:  2008-02-07       Impact factor: 3.582

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  31 in total

Review 1.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

2.  CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Authors:  Daniela Sicoli; Xuanmao Jiao; Xiaoming Ju; Marco Velasco-Velazquez; Adam Ertel; Sankar Addya; Zhiping Li; Sebastiano Andò; Alessandro Fatatis; Bishnuhari Paudyal; Massimo Cristofanilli; Mathew L Thakur; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2014-12-01       Impact factor: 12.701

3.  Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing Senescence.

Authors:  Anthony J Bainor; Fang-Ming Deng; Yu Wang; Peng Lee; David J Cantor; Susan K Logan; Gregory David
Journal:  Cancer Res       Date:  2017-08-14       Impact factor: 12.701

4.  Evaluation of ERG responsive proteome in prostate cancer.

Authors:  Shyh-Han Tan; Bungo Furusato; Xueping Fang; Fang He; Ahmed A Mohamed; Nicholas B Griner; Kaneeka Sood; Sadhvi Saxena; Shilpa Katta; Denise Young; Yongmei Chen; Taduru Sreenath; Gyorgy Petrovics; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Satya Saxena; Shiv Srivastava
Journal:  Prostate       Date:  2013-09-21       Impact factor: 4.104

5.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Celine Lefebvre; Mariano J Alvarez; Mireia Castillo-Martin; Tian Zheng; James A Eastham; Anuradha Gopalan; Kenneth J Pienta; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

6.  Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.

Authors:  Fan Wang; Lin Liu; Yu Tong; Linfeng Li; Yanfeng Liu; Wei-Qiang Gao
Journal:  Cell Cycle       Date:  2020-02-02       Impact factor: 4.534

7.  RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.

Authors:  Hyejin Cho; Tali Herzka; Wu Zheng; Jun Qi; John E Wilkinson; James E Bradner; Brian D Robinson; Mireia Castillo-Martin; Carlos Cordon-Cardo; Lloyd C Trotman
Journal:  Cancer Discov       Date:  2014-01-20       Impact factor: 39.397

8.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  Luminal cells are favored as the cell of origin for prostate cancer.

Authors:  Zhu A Wang; Roxanne Toivanen; Sarah K Bergren; Pierre Chambon; Michael M Shen
Journal:  Cell Rep       Date:  2014-08-28       Impact factor: 9.423

10.  Dissection of Individual Prostate Lobes in Mouse Models of Prostate Cancer to Obtain High Quality RNA.

Authors:  Areg Zingiryan; Nicholas H Farina; Kristiaan H Finstad; Janet L Stein; Jane B Lian; Gary S Stein
Journal:  J Cell Physiol       Date:  2016-04-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.